“I believe that with the evidence of yesterday’s mergers, specifically the astoundingly well-priced purchase of Immunomedics (IMMU) by Gilead, that this is an area that should be speculated upon. Biotech’s time has come once again,” declares the author of today’s article, commenting on the deluge of M&A activity that took place on Monday (resulting in it being dubbed “Merger Monday”). How is this self-confessed “dummy when it comes to picking out up-and-coming biotechs” approaching investing in the space? CLICK HERE.